A Phase 2 interventional study of SU011248/Trastuzumab in Breast Neoplasms, sponsored by Pfizer. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing sunitinib in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Sunitinib · Breast Neoplasms.
Among the 29 studies testing sunitinib in Breast Neoplasms, this one is the 15th largest by enrollment, is one of 6 that started in 2006, is one of 13 in phase 2, and was the 3rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →1 of the 29 studies testing sunitinib in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 65+
By country, each count listing its studies:
Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 4 · Phase 4 1
First in 2004; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 29 interventional studies. Of the 25 that completed or were terminated, 18 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 72nd largest by enrollment of the 121 interventional ones that give a count, is one of 9 that started in 2006, is one of 43 in phase 2, and was the 22nd registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing sunitinib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SU011248/Trastuzumab
Drug pages: SunitinibStudies of SunitinibSunitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
Percentage of Participants With Overall Confirmed Objective Disease Response
Objective disease response =participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target and non-target lesions. A PR was defined as a \> = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions associated to a non-progressive disease response for the non target lesions.
Time frame: From start of treatment through 18 months
Duration of Response (DR)
Time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of objective tumor progression or death due to any cause. If tumor progression data included more than 1 date, the first date was used. DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1) divided by 7.
Time frame: From start of treatment through 18 months
Percentage of Participants With Clinical Benefit
Percent of participants with confirmed CR, PR or stable disease (SD) for at least 24 weeks on study according to RECIST.CR was defined as disappearance of all target and non-target lesions.PR was defined as \>=30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions associated to non-progressive disease response for non target lesions.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started.
Time frame: From start of treatment through 18 months
Progression Free Survival (PFS)
Time from first dose of study treatment to first documentation of objective tumor progression, or to death on-study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS was calculated as (first event date minus first dose date +1) divided by 7.
Time frame: From start of treatment through 18 months
Time to Progression (TTP)
Time from first dose of study treatment to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP was calculated as (first event date minus first dose date +1) divided by 7.
Time frame: From start of treatment through 18 months
Overall Survival (OS)
Time from first dose of study treatment to first documentation of death due to any cause. OS was calculated as (date of death minus first dose date +1) divided by 7 \* 4.33.
Time frame: From start of study treatment until death or 2 years from first study treatment
Probability of Survival at One Year
One- year survival probability was estimated using the Kaplan-Meier method.
Time frame: From start of study treatment until death or 2 years from first study treatment
EORTC QLQ-C30
EORTC QLQ-C30 scales consist of 30 questions: functional (physical/role/cognitive/emotional/ social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea). Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.
Time frame: From start of treatment through 18 months
EORTC QLQ (BR23)
BR23: consisted of 23 questions which measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
Time frame: From start of treatment through 18 months
Dose-corrected Trough Plasma Concentrations (Ctrough) of Sunitinib
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
Time frame: Predose on Day 1 of Cycle 3 and 5
Dose-corrected Ctrough of SU-012662 (Sunitinib's Metabolite)
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
Time frame: Predose on Day 1 of Cycle 3 and 5
Dose-corrected Ctrough of Total Drug (Sunitinib + SU-012662)
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
Time frame: Predose on Day 1 of Cycle 3 and 5
| Milestone | Trastuzumab + Sunitinib |
|---|---|
| Started | 60 |
| Completed | 2 |
| Not completed | 58 |
| Withdrew: Adverse event | 11 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lack of efficacy | 44 |
| Withdrew: Death | 1 |
| Withdrew: Other | 1 |
Objective disease response =participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target and non-target lesions. A PR was defined as a \> = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions associated to a non-progressive disease response for the non target lesions.
| percentage of participants | Trastuzumab + Sunitinib |
|---|---|
| Percentage of Participants With Overall Confirmed Objective Disease Response | 36.8 (24.4 to 50.7) |
Time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of objective tumor progression or death due to any cause. If tumor progression data included more than 1 date, the first date was used. DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1) divided by 7.
| weeks | Trastuzumab + Sunitinib |
|---|---|
| Duration of Response (DR) | 25.6 (22.4 to 32.9) |
Percent of participants with confirmed CR, PR or stable disease (SD) for at least 24 weeks on study according to RECIST.CR was defined as disappearance of all target and non-target lesions.PR was defined as \>=30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions associated to non-progressive disease response for non target lesions.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started.
| Percentage of Participants | Trastuzumab + Sunitinib |
|---|---|
| Percentage of Participants With Clinical Benefit | 56.1 (42.4 to 69.3) |
Time from first dose of study treatment to first documentation of objective tumor progression, or to death on-study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS was calculated as (first event date minus first dose date +1) divided by 7.
| Weeks | Trastuzumab + Sunitinib |
|---|---|
| Progression Free Survival (PFS) | 28.0 (24.1 to 31.3) |
Time from first dose of study treatment to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP was calculated as (first event date minus first dose date +1) divided by 7.
| weeks | Trastuzumab + Sunitinib |
|---|---|
| Time to Progression (TTP) | 26.0 (23.3 to 31.1) |
Time from first dose of study treatment to first documentation of death due to any cause. OS was calculated as (date of death minus first dose date +1) divided by 7 \* 4.33.
| months | Trastuzumab + Sunitinib |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
One- year survival probability was estimated using the Kaplan-Meier method.
| percentage of 1-year survival | Trastuzumab + Sunitinib |
|---|---|
| Probability of Survival at One Year | 91.2 (80.2 to 96.3) |
EORTC QLQ-C30 scales consist of 30 questions: functional (physical/role/cognitive/emotional/ social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea). Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.
| scores on a scale | Trastuzumab + Sunitinib |
|---|---|
| Function Score: Global health (n=28) | 56.0 ± 21.4 |
| Function Score: Physical function (n=28) | 75.2 ± 16.8 |
| Function Score: Role function (n=28) | 60.1 ± 28.8 |
| Function Score: Cognitive function (n=28) | 84.5 ± 21.7 |
| Function Score: Emotional function (n=28) | 66.1 ± 27.5 |
| Function Score: Social function (n=28) | 66.7 ± 28.3 |
| Symptom Score: Fatigue (n=28) | 45.0 ± 25.3 |
| Symptom Score: Pain (n=28) | 36.9 ± 25.8 |
| Symptom Score: Nausea/vomiting (n=28) | 6.5 ± 10.5 |
| Symptom Score: Dyspnea (n=28) | 26.2 ± 30.6 |
| Symptom Score: Loss of appetite (n=28) | 20.2 ± 24.6 |
| Symptom Score: Insomnia (n=28) | 29.8 ± 27.7 |
| Symptom Score: Constipation (n=27) | 14.8 ± 26.7 |
| Symptom Score: Diarrhea (n=27) | 32.1 ± 32.7 |
| Symptom Score: Financial difficulty (n=28) | 17.9 ± 29.4 |
BR23: consisted of 23 questions which measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
| scores on a scale | Trastuzumab + Sunitinib |
|---|---|
| Function Score : Body image (n=27) | 76.4 ± 29.5 |
| Function Score: Sexual function (n=24) | 14.6 ± 16.5 |
| Function Score: Sexual enjoyment (n=10) | 33.3 ± 15.7 |
| Others :Future health perspective (n=27) | 45.7 ± 34.8 |
| Symptom Score: systemic therapy side effects(n=27) | 21.7 ± 15.8 |
| Symptom Score: Breast (n=27) | 19.4 ± 23.6 |
| Symptom Score: Arm (n=27) | 21.0 ± 23.9 |
| Others :Upset of hair loss (n=6) | 44.4 ± 27.2 |
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
| nanograms (ng)/milliliter (mL) | Trastuzumab + Sunitinib |
|---|---|
| Day 1 (Cycle 3) | 53.5 ± 27.6 |
| Day 1 (Cycle 5) | 55.0 ± 24.8 |
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
| ng/mL | Trastuzumab + Sunitinib |
|---|---|
| Day 1 (Cycle 3) | 26.7 ± 14.4 |
| Day 1 (Cycle 5) | 24.7 ± 12.5 |
Ctrough = the concentration prior to study drug administration. Dose-corrected values were reported, the reference dose was 37.5 mg.
| ng/mL | Trastuzumab + Sunitinib |
|---|---|
| Day 1 (Cycle 3) | 80.2 ± 39.9 |
| Day 1 (Cycle 5) | 79.7 ± 36.3 |
Collected over From time of informed consent signing (SAEs) or first study treatment (AEs) through 18 months and including 28 calendar days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab + Sunitinib | — | 25/60 (41.7%) | 59/60 (98.3%) |
| Event | Trastuzumab + Sunitinib |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/60 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/60 |
| PancreatitisGastrointestinal disorders | 2/60 |
| VomitingGastrointestinal disorders | 2/60 |
| AstheniaGeneral disorders | 2/60 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/60 |
| HypertensionVascular disorders | 2/60 |
| AnaemiaBlood and lymphatic system disorders | 1/60 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/60 |
| Cardiac failureCardiac disorders | 1/60 |
| Event | Trastuzumab + Sunitinib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 36/60 |
| AstheniaGeneral disorders | 29/60 |
| DysgeusiaNervous system disorders | 27/60 |
| HypertensionVascular disorders | 25/60 |
| VomitingGastrointestinal disorders | 21/60 |
| Mucosal inflammationGeneral disorders | 21/60 |
| DyspepsiaGastrointestinal disorders | 20/60 |
| NauseaGastrointestinal disorders | 20/60 |
| FatigueGeneral disorders | 19/60 |
| HeadacheNervous system disorders | 18/60 |
| Age Continuous(Years) | Trastuzumab + Sunitinib |
|---|---|
| Mean | 55.1 ± 12.8 |
| Sex: Female, Male(Participants) | Trastuzumab + Sunitinib |
|---|---|
| Female | 60 |
| Male | 0 |
| EORTC QLQ-C30(scores on a scale) | Trastuzumab + Sunitinib |
|---|---|
| Function Score: Global health (n=48) | 66.8 ± 26.8 |
| Function Score: Physical function (n=49) | 79.5 ± 21.3 |
| Function Score: Role function (n=49) | 76.2 ± 30.0 |
| Function Score: Cognitive function (n=49) | 82.0 ± 25.6 |
| Function Score: Emotional function (n=49) | 62.8 ± 26.4 |
| Function Score: Social function (n=49) | 75.5 ± 29.9 |
| Symptom Score: Fatigue (n=49) | 35.6 ± 27.6 |
| Symptom Score: Pain (n=49) | 38.8 ± 33.7 |
| Symptom Score: Nausea/vomiting (n=49) | 7.1 ± 18.0 |
| Symptom Score: Dyspnea (n=48) | 22.9 ± 28.5 |
| Symptom Score: Loss of appetite (n=49) | 14.3 ± 28.1 |
| Symptom Score: Insomnia (n=49) | 35.4 ± 31.5 |
| Symptom Score: Constipation (n=48) | 18.1 ± 32.9 |
| Symptom Score: Diarrhea (n=49) | 6.8 ± 15.2 |
| Symptom Score: Financial difficulty (n=48) | 15.3 ± 28.3 |
| EORTC QLQ Breast Cancer Module (BR23)(scores on a scale) | Trastuzumab + Sunitinib |
|---|---|
| Function Score : Body image (n=46) | 77.2 ± 25.4 |
| Function Score: Sexual function (n=44) | 21.6 ± 24.5 |
| Function Score: Sexual enjoyment (n=15) | 53.3 ± 21.1 |
| Symptom Score: Arm (n=48) | 23.8 ± 25.3 |
| Symptom Score: Breast (n=47) | 25.9 ± 27.5 |
| Symptom Score: systemic therapy side effects(n=48) | 17.2 ± 17.4 |
| Others :Upset of hair loss (n=6) | 50.0 ± 27.9 |
| Others :Future health perspective (n=48) | 39.6 ± 32.0 |
The record gives a start of Feb 2006, a primary completion of Apr 2009 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sunitinib · Trastuzumab